Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Actinium Pharmaceuticals Inc (NY: ATNM )

8.605 -0.255 (-2.88%)
Streaming Delayed Price Updated: 3:35 PM EDT, May 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 436,069
Open 8.790
Bid (Size) 8.590 (6)
Ask (Size) 8.620 (2)
Prev. Close 8.860
Today's Range 8.200 - 8.814
52wk Range 4.000 - 10.24
Shares Outstanding 21,331,314
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Cheap Biotech Stocks to Buy Now: May 2024
Many of these cheap biotech stocks are on their way to achieving FDA approval for their drugs to enter the market. 
Via InvestorPlace
Exposures Product Safety
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
Via AB Newswire

Performance

YTD
+61.75%
+61.75%
1 Month
+20.01%
+20.01%
3 Month
+23.99%
+23.99%
6 Month
+99.65%
+99.65%
1 Year
+11.18%
+11.18%

More News

Read More
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
Via AB Newswire
ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024
Via InvestorPlace
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Via Investor's Business Daily
(ATNM) - Analyzing Actinium Pharmaceuticals's Short Interest
Via Benzinga
Actinium Pharmaceuticals (ATNM) Leads Biotech Innovation Amid Economic Uncertainty
Via AB Newswire
Topics Economy
Exposures Interest Rates
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest
Via AB Newswire
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
Via InvestorPlace
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
Via AB Newswire
Actinium Pharmaceuticals (ATNM) Spearheading the Future of Oncology with Iomab-ACT’s Innovative Clinical Trial
Via AB Newswire
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Actinium Pharmaceuticals Inc (ATNM) Targets Breakthrough in Cancer Therapy: Proprietary Production of Vital Isotope Sparks Industry Buzz and Share Surge
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Actinium Pharmaceuticals Inc. (ATNM) Leads Breakthroughs in Targeted Radiotherapy with Iomab-B and Strategic Production of Actinium-225
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
High-Risk, High-Reward: Little-Known Biotech Stock ATNM Could Soar on Breakthrough Cancer Treatment
Via InvestorPlace
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) launches strategic initiative focused on the manufacture of the highly sought after medical isotope Actinium-225 (Ac-225)
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
Actinium Pharma – Pivotal Results From Key New Drug In The Fight Against Cancer
Via Benzinga
Actinium Pharma Cratered 37% Over Two Days — Here's Why, According To CEO Sandesh Seth
Via Investor's Business Daily
Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029
Via FinancialNewsMedia
Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.